Cargando…
Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma
Functional gene expression signatures (FGES) from pretreatment biopsy samples have been used to predict the responses of metastatic melanoma to immune checkpoint blockade (ICB) therapies. However, there are no predictive FGE signatures from patients receiving treatment. Here, using the Elastic Net R...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855743/ https://www.ncbi.nlm.nih.gov/pubmed/36671443 http://dx.doi.org/10.3390/biom13010058 |
_version_ | 1784873450404315136 |
---|---|
author | Chen, Shuzhao Zhang, Limei Lin, Haocheng Liang, Yang Wang, Yun |
author_facet | Chen, Shuzhao Zhang, Limei Lin, Haocheng Liang, Yang Wang, Yun |
author_sort | Chen, Shuzhao |
collection | PubMed |
description | Functional gene expression signatures (FGES) from pretreatment biopsy samples have been used to predict the responses of metastatic melanoma to immune checkpoint blockade (ICB) therapies. However, there are no predictive FGE signatures from patients receiving treatment. Here, using the Elastic Net Regression (ENLR) algorithm, we analyzed transcriptomic and matching clinical data from a dataset of patients with metastatic melanoma treated with ICB therapies and produced an FGE signature for pretreatment (FGES-PRE) and on-treatment (FGES-ON). Both the FGES-PRE and FGES-ON signatures are validated in three independent datasets of metastatic melanoma as the validation set, achieving area under the curve (AUC) values of 0.44–0.81 and 0.82–0.83, respectively. Then, we combined all test samples and obtained AUCs of 0.71 and 0.82 for the FGES-PRE and FGES-ON signatures, respectively. The FGES-ON signatures had a higher predictive value for prognosis than the FGES-PRE signatures. The FGES-PRE and FGES-ON signatures were divided into high- and low-risk scores using the signature score mean value. Patients with a high FGE signature score had better survival outcomes than those with low scores. Overall, we determined that the FGES-ON signature is an effective biomarker for metastatic melanoma patients receiving ICB therapy. This work would provide an important theoretical basis for applying FGE signatures derived from on-treatment tumor samples to predict patients’ therapeutic response to ICB therapies. |
format | Online Article Text |
id | pubmed-9855743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98557432023-01-21 Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma Chen, Shuzhao Zhang, Limei Lin, Haocheng Liang, Yang Wang, Yun Biomolecules Article Functional gene expression signatures (FGES) from pretreatment biopsy samples have been used to predict the responses of metastatic melanoma to immune checkpoint blockade (ICB) therapies. However, there are no predictive FGE signatures from patients receiving treatment. Here, using the Elastic Net Regression (ENLR) algorithm, we analyzed transcriptomic and matching clinical data from a dataset of patients with metastatic melanoma treated with ICB therapies and produced an FGE signature for pretreatment (FGES-PRE) and on-treatment (FGES-ON). Both the FGES-PRE and FGES-ON signatures are validated in three independent datasets of metastatic melanoma as the validation set, achieving area under the curve (AUC) values of 0.44–0.81 and 0.82–0.83, respectively. Then, we combined all test samples and obtained AUCs of 0.71 and 0.82 for the FGES-PRE and FGES-ON signatures, respectively. The FGES-ON signatures had a higher predictive value for prognosis than the FGES-PRE signatures. The FGES-PRE and FGES-ON signatures were divided into high- and low-risk scores using the signature score mean value. Patients with a high FGE signature score had better survival outcomes than those with low scores. Overall, we determined that the FGES-ON signature is an effective biomarker for metastatic melanoma patients receiving ICB therapy. This work would provide an important theoretical basis for applying FGE signatures derived from on-treatment tumor samples to predict patients’ therapeutic response to ICB therapies. MDPI 2022-12-27 /pmc/articles/PMC9855743/ /pubmed/36671443 http://dx.doi.org/10.3390/biom13010058 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Shuzhao Zhang, Limei Lin, Haocheng Liang, Yang Wang, Yun Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma |
title | Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma |
title_full | Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma |
title_fullStr | Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma |
title_full_unstemmed | Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma |
title_short | Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma |
title_sort | functional gene expression signatures from on-treatment tumor specimens predict anti-pd1 blockade response in metastatic melanoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855743/ https://www.ncbi.nlm.nih.gov/pubmed/36671443 http://dx.doi.org/10.3390/biom13010058 |
work_keys_str_mv | AT chenshuzhao functionalgeneexpressionsignaturesfromontreatmenttumorspecimenspredictantipd1blockaderesponseinmetastaticmelanoma AT zhanglimei functionalgeneexpressionsignaturesfromontreatmenttumorspecimenspredictantipd1blockaderesponseinmetastaticmelanoma AT linhaocheng functionalgeneexpressionsignaturesfromontreatmenttumorspecimenspredictantipd1blockaderesponseinmetastaticmelanoma AT liangyang functionalgeneexpressionsignaturesfromontreatmenttumorspecimenspredictantipd1blockaderesponseinmetastaticmelanoma AT wangyun functionalgeneexpressionsignaturesfromontreatmenttumorspecimenspredictantipd1blockaderesponseinmetastaticmelanoma |